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ABSTRACT
Clinicians frequently use computer-based neurocognitive assessments to aid
in the diagnosis and man-agement of Sport-Related Concussion (SRC). With
practitioners using varied Neuro-Cognitive Assess-ment Tools (NCAT), questions
arise concerning differences among NCAT and how these differences may affect
patient care. The purpose of the current study is to offer a comparative analysis
of two widely accepted, commercially available computer-based neurocognitive
testing modalities in the adolescent con-cussed athlete.
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INTRODUCTION
The incidence of sport-related concussion (SRC) is
a growing problem in the field of sports medicine.
Zhang et al.1 demonstrated that the incidence
of concussion in the US population is increasing,
particularly in adolescent populations. The
assessment and management of patients following a
head injury can be difficult. There is ongoing research
within the healthcare community for the optimal
assessment and treatment protocol for these patients.
Standard practices are evolving, and consensus
documents attempt to suggest “best evidence”
standards for the patient with SRC.2,3 Neurocognitive
Assessment Testing (NCAT) is a validated objective
diagnostic and prognostication tool.4 NCATs are used
by healthcare providers in the clinic setting, as well as
in athletic training rooms to assist the management
of patients with concussion.
Computer-based testing is now commonly used
in tandem with symptom scoring tools.5 There
are several commercially available NCAT products
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competing to capture shares of a burgeoning
market. It is unclear which product is superior with
an increasing number of NCATs available. There
is insufficient evidence to establish benefit in
using a specific NCAT product for the evaluation,
management, or monitoring of patients with SRC.
There appears to be no clear clinical practice standard
for the use of NCATs outside of manufacturer
guidelines. Practitioner preference and familiarity
with an NCAT product leads to varying practices
among healthcare providers.
NCATs offer several potential advantages over the
archetypal paper neuropsychological tests, such as
the Sport Concussion Assessment Tool (SCAT5), in the
assessment of patients with SRC. The ability of NCAT’s
to diagnose, rule out, and monitor recovery from SRC
is unclear as many external factors can influence the
utility of NCATs. There is a lack of evidence to support
the reliability, validity, or clinical utility of NCATs. The
literature provides some support for the convergent
validity of NCAT tests.6,7 The results of reliability
studies are variable.4 It has been shown that a
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score on an NCAT which indicates a good cognitive
function is useful in identifying patients without
concussion.8 However, the utility of an NCAT to rule
out SRC is not well documented.9,10 There have
been concerns raised about the validity of these tests
outside the acute 48-hour time frame. It is generally
agreed that NCATs should not be used in isolation to
diagnose or to guide the management of SRC until
there is more evidence supporting the reliability and
validity of NCATs.
The purpose of this retrospective cohort study is
to characterize important translational metrics in
athletic patients affected by sport-related concussion.
The investigation determined differences in the time
to the initiation of a return to play protocol (IRTP), the
time to return to play (RTP), the level of impairment
and concussion symptoms at the initial assessment,
at the IRTP and the RTP when the clinician was
assisted by either the ImPACT® or C3Logix® NCAT.
The investigation tested two hypotheses. First, there
would be a difference between the C3 Logix® vs.
ImPACT® scoring in the IRPT and RTP, and second,
isolated NCAT symptom scores alone are not
indicative of RTP; the majority of this decision relies
on other factors to be managed by clinician care.

required.
PROCEDURE
Patients included in this study participated in the
Sports Medicine Clinic’s baseline concussion testing
program. Upon presentation, the treating physician
performed a post-injury neurocognitive assessment
and then managed the patient as is customary and
usual to their practice. All patients were evaluated
on their initial visit to the clinic with either the
IMPACT® or C3Logix® NCAT modality, depending on
the preference of the treating physician. ImPACT®
computerized testing is a widely accepted, wellmarketed platform. There is a growing amount of
research supporting its utilization in an athletic
medical setting.11 ImPACT® testing includes tests of
verbal and visual memory, reaction time, symptom
score, visual-motor speed, and impulse control.
C3Logix® is a different platform developed by the
Cleveland Clinic, has similar testing batteries, but
also includes other metrics such as a vestibular
baseline component.12 Repeat testing occurred as
deemed necessary by the treating physician until it
was determined that the patient was able to begin
the return to play protocol.

METHODS

DATA ENTRY

Patients in the current study were entered into the
study from patients treated by two sports medicine
clinics from fall 2015 to spring 2017. A search of the
practices’ electronic medical record (Allscripts EHR
System, Allscripts Healthcare Solutions, Chicago, IL,
and EPIC Electronic Medical record) was conducted
during November 2017. All records were identified
with the diagnosis code of S06.0X0 (concussion
without loss of consciousness), S06.0X9 (concussion
with loss of consciousness of unspecified duration),
or S06.0X1 (concussion with loss of consciousness
less than 30 minutes). Patient records were included
if the patient was 13-18 years of age, participated
in an interscholastic athletic program, and had a
diagnosis of an SRC. The project was approved by the
University Internal Review Board (IRBNet ID# 6273213). The current study was a retrospective review of
records involving procedures that are considered the
standard of care. No patient informed consent was

The records for all identified patients were reviewed
by a single research assistant in order to identify the
study’s test variables. Patient identifying information
was not extracted from the patient records. A
second investigator reviewed the extracted data
for accuracy before data analysis. The investigator
identified the patient demographic information, the
initial date of injury, date of the initial evaluation,
the date of subsequent evaluations, the results of all
clinical tests, NCAT results, date of the initiation of
the return to play protocol, and the date of return to
play. All data were entered into a spreadsheet and
then imported into SPSS for analysis.
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STATISTICAL ANALYSIS
Means and standard deviations for all study variables
were calculated. All dependent variables followed
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a normal distribution determined by the ShapiroWilk test. The variance of dependent variables
differed between groups, so Welch’s t-tests were
performed to determine between-group differences
in symptom severity, duration of symptoms, time
to the initiation of the return to play protocol, and
time to return to play. Correlation analysis was used
to test the relationship between symptom severity,
the time to return to play protocol, and the time to
return to play. Correlation coefficients r = 0 – 0.25
were considered of no correlation, r = 0.26 – 0.50
weak correlation, 0.51 – 0.75 moderate correlation,
and r > 0.75 strong correlation. Multiple regression
analysis was used to determine if the initial symptom
score of reaction time predicted either the time to
initiation of the return to play protocol or the time
to return to play. Statistical analysis was performed
with SPSS 24.0 (SPSS Chicago, IL), and statistical
significance was determined at p < 0.05.

RESULTS
Two hundred twenty-two records (222) were entered
into the study; five (5) records were missing either
the date of injury or the date of the initial evaluation
and were excluded from the investigation. Two
hundred seventeen (217) records were entered
into the analysis. One hundred ninety-two (192)
records were evaluated using the ImPACT® testing,
and twenty-five (25) were evaluated using the C3
Logix® system at the time of the initial evaluation. No
patients included in the study received more than
one recorded concussion during the data collection
period. The mean time between the date of injury
(DOI) and the initial evaluation (IEVAL), initiating the
return to play protocol (IRPT) and the patients’ return
to play (RPT) can be found in Table 1. There was not
a difference (t = -1.226, P = 0.22) in the time between

TABLE 1. Time (days) between the injury and the initial evaluation (IEVAL), the initiation of the return to play
protocol (IRTP), and return to play (RTP), mean time ± standard deviation.

TABLE 2. Symptom score at the initial evaluation (IEVAL), the initiation of the return to play protocol (IRTP) and
return to play (RTP), mean ± standard deviation (mean ± standard deviation) by each device, and the mean of
the two devices.

TABLE 3. Reaction time (seconds) at the initial evaluation (IEVAL), the initiation of the return to play protocol
(IRTP) and return to play (RTP), mean ± standard deviation (mean ± standard deviation) by each device, and the
mean of the two devices.
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the DOI and the IEVAL, IRTP or the RTP between
patients evaluated using C3 Logix® and ImPACT®. The
mean symptom score (Table 2) across both devices
decreased during the time between IEVAL and
RTP. Reaction time decreased between IEVAL and
RTP (Table 3). The mean reaction time across both
devices at the IEVAL was 0.743 ± 0.016 sec (n = 155).
The mean reaction time across both devices at the
RTP was 0.619 ± 0.11 sec (n = 95).
Weak to moderate correlations (Table 4) were found
between symptom scores, reaction time, IRTP, and
RTP. The time between the DOI and IEVAL did not
correlate with symptom scores or reaction time. The
strongest correlation (r = 0.551, P = 0.01) was found
between the time to IRTP and RTP. The symptom
score at the IRTP had a weak correlation (r = 0.464,
P < 0.001) to the IEVAL symptom score. The reaction
time and the symptom score at the IEVAL had a
moderate correlation (r = 0.353, P < 0.001). Multiple
regression analysis revealed that the symptom
score at the IEVAL predicted the IRPT (r2 = 0.214, P
< 0.001), reaction time factor but did not affect the
regression model (P = 0.959) while the regression

equation did not predict the RTP (r2 = 0.010, P =
0.91).
DISCUSSION
The purpose of the current study was to compare
two popular and commercially used neurocognitive
testing modalities in adolescent concussed athletes.
Graham et al8 advocate for increased reliance on
subjective means for the clinician to employ in their
diagnoses and management of concussion injuries.
Higgins et al13 and Simon et14 al identified ImPACT®
and C3 Logix® as a valid means for testing symptom
scores, respectively. Our results indicate the NCATs
tested (C3 Logix® and ImPACT®) did not show a
difference in their prediction of IRPT based upon
symptom score alone. Two hundred seventeen (217)
records were entered into the study for analysis,
with one hundred ninety-two (192) evaluated using
ImPACT® testing, and twenty-five (25) using C3
Logix® testing. The two groups had a similar level
of concussion symptoms at the initial evaluation.
The mean time between IEVAL and initiation if
IRTP protocol was 15 ± 18 days. The considerable
deviations to this value are likely attributed to

Table 4. Correlation coefficients, initiate the return to play protocol (IRPT), return to play (RPT), initial
evaluation (IE-VAL).
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the variability in the level of symptom severity
and clinician care based upon other subjective or
objective criteria, such as individual medical history
or presenting symptoms not captured by tested
NCAT criteria. There was not a difference in the
time between the DOI and RTP between patients
evaluated with C3 Logix® (12.1 ± 4.9 days) and
ImPACT® (15.6 ± 19.8 days). This suggests there is
not a major difference in the predictive nature of the
NCAT testing modalities studied, which is counter to
the hypothesis at the onset of the study.
Individuals that had an IRTP greater-than 12
days tended to have a greater symptom score at
presentation, and individuals that had an IRTP lessthan 12 days tended to have a lesser symptom score
at presentation with C3 Logix® testing. Individuals
that had an IRTP greater-than 15 days tended to
have a greater symptom score at presentation, and
individuals that had an IRTP less-than 15 days tended
to have a lesser symptom score at presentation with
ImPACT® testing. Regression analysis revealed that
the symptom score at the IEVAL predicted the IRTP
(r2 = 0.21, p < 0.001) but not the RTP (r2 = 0.01, p
= 0.91). This is consistent with known research that
symptom score is indicative of IRTP.15 However, the
low R2 value indicates that still most of the influence
comes from other factors that are involved in the
managing and rehabilitation for concussion injuries.
Mean symptom scores decreased during the time
between IEVAL and RTP for both C3 Logix® and
ImPACT® testing. There was no difference observed
in the symptom scores at IEVAL between C3 Logix®
and ImPACT®. For patients participating in the study,
neither data set was more severely injured based
upon presenting symptom score, and the pathology
of injury recovery progressed equally for both
testing modalities. Patients in the study followed
a standardized recovery protocol derived from the
Berlin consensus guidelines.2
The results of the current study must be reviewed
in light of the following limitations. The study was
limited by the disproportionate number tested
using the two NCAT testing modalities, with a larger
patient population tested with ImPACT® (n = 192)
than C3 Logix® (n = 25). There was not a statistical
difference in the symptom scores between the two
devices. Due to the disproportioned sample sizes,
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the current study did not attempt to establish
equivalence between the measures made using the
two devices. The purpose of the investigation was
to explore if differences between the two devices
could be found not if the two devices are equivalent.
The range of the scores was the same between
the two devices. Five records were excluded due
to incomplete data reducing the sample size to
217. Patients were evaluated and managed by five
physicians with varying training. However, all were
experienced in the treatment of concussed athletes.
The largest number of patients were managed by a
single investigator. The finding of long reaction time
at IEVAL for patients evaluated with ImPACT® must
be interpreted with caution. The two tests do not
measure reaction time using the same criteria and
this is likely a spurious finding. All of the clinicians
managed their patients using the best available
clinical evidence. Lastly, there was no attempt to
control for concussion history or other comorbidities.
It is likely concussion history and comorbidities
occurred at equal rates in patients tested with both
NCATs.
Zhang, et al1 identified a rise in the incidence of
concussion in the adolescent athletic population;
the increase in the number of concussive injuries
calls for an increase in the understanding of how
to diagnose and manage these patients. Further
research connecting the increasingly widespread use
of NCATs in both the office and sideline environment
may be beneficial to identify a potential correlation
between these two values. Our data agree with
previous literature on the application of NCATs in the
diagnosis and management of concussion injuries.
The relatively large deviation in IRTP and RTP
for both testing devices is most likely attributed
to the individualized patient care provided by
clinicians, which concurs with Johnson et al.5 and
the suggestion that NCATs can provide clinicians a
valid objective means to provide direct care to treat
targeted deficiencies in neurocognitive function,
such as balance or visual acuity insufficiencies. Dessy
et al11 identified that no single test is sufficient
for the stand-alone diagnoses of sports-related
concussions. Arrieux et al4 have identified there are
still questions to the use of NCATs for an accurate
diagnosis of concussion injuries. Our results expand
upon these issues, indicating that two of the most
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common NCAT yield similar results; however, the
largest influence remains in the tailored patient care
provided by the clinician.
Research suggests as high as fifty-percent of
concussions may go unreported16, which may
pose challenges for healthcare providers. Further
research and advocacy on the increasing use of
NCATs may propose an actionable solution to
decrease the number of unreported concussions.
Additional research into the development of a
specialized protocol for NCAT derived symptom
scores, utilizing a variety of modalities, may be
beneficial in the treatment of future patients. This
may serve to provide screening tools that can assist
the clinical judgment of healthcare providers. There
may be circumstances that clinicians determine to
remove an athlete from play and enter concussion
protocol based upon other subjective or objective
criteria when NCAT scores fall below the concussion
threshold. Further research into the prevalence of
this scenario may prove beneficial to understand the
role NCATs play in the initial diagnoses of SRC injuries
and their function as a means to measure recovery
from the injury and provide recommendations for the
return to play.
The current study focused on the quality and
comparison of two widely used NCAT devices in their
application to the concussed athlete as a means to
predict a return to play. It did not focus on major
differences between the two testing protocols and
procedures directed by the respective companies.
Our results indicated that NCATs provide a minority of
predictive means for athlete return to play from the
initial injury and showed two of the most widely used
devices did not display a major difference in this area.
Presenting symptom score alone was not sufficient to
predict IRTP; however, it remained the most weighted
testing measure across testing devices. The results
of this study concur with established literature that
the most important aspect to the individualized
care of the concussed athlete remains the expertise
and patient knowledge possessed by the managing
clinician.
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